|
1
|
Akira S and Hemmi H: Recognition of
pathogen-associated molecular patterns by TLR family. Immunol Lett.
85:85–95. 2003.
|
|
2
|
Wagner H: The immunobiology of the TLR9
subfamily. Trends Immunol. 25:381–386. 2004.
|
|
3
|
Matsumoto M, Funami K, Tanabe M, et al:
Subcellular localization of Toll-like receptor 3 in human dendritic
cells. J Immunol. 171:3154–3162. 2003.
|
|
4
|
Nishiya T and DeFranco AL:
Ligand-regulated chimeric receptor approach reveals distinctive
subcellular localization and signaling properties of the Toll-like
receptors. J Biol Chem. 279:19008–19017. 2004.
|
|
5
|
Schmausser B, Andrulis M, Endrich S, et
al: Expression and subcellular distribution of toll-like receptors
TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter
pylori infection. Clin Exp Immunol. 136:521–526. 2004.
|
|
6
|
Leifer CA, Kennedy MN, Mazzoni A, Lee C,
Kruhlak MJ and Segal DM: TLR9 is localized in the endoplasmic
reticulum prior to stimulation. J Immunol. 173:1179–1183. 2004.
|
|
7
|
Palm NW and Medzhitov R: Pattern
recognition receptors and control of adaptive immunity. Immunol
Rev. 227:221–233. 2009.
|
|
8
|
Schmausser B, Andrulis M, Endrich S,
Müller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and
TLR9 on gastric carcinoma cells: an implication for interaction
with Helicobacter pylori. Int J Med Microbiol. 295:179–185.
2005.
|
|
9
|
Schaefer TM, Desouza K, Fahey JV, Beagley
KW and Wira CR: Toll-like receptor (TLR) expression and
TLR-mediated cytokine/chemokine production by human uterine
epithelial cells. Immunology. 112:428–436. 2004.
|
|
10
|
Bowman CC, Rasley A, Tranguch SL and
Marriott I: Cultured astrocytes express toll-like receptors for
bacterial products. Glia. 43:281–291. 2003.
|
|
11
|
Platz J, Beisswenger C, Dalpke A, et al:
Microbial DNA induces a host defense reaction of human respiratory
epithelial cells. J Immunol. 173:1219–1223. 2004.
|
|
12
|
Mempel M, Voelcker V, Köllisch G, et al:
Toll-like receptor expression in human keratinocytes: nuclear
factor kappaB controlled gene activation by Staphylococcus
aureus is toll-like receptor 2 but not toll-like receptor 4 or
platelet activating factor receptor dependent. J Invest Dermatol.
121:1389–1396. 2003.
|
|
13
|
Zaks-Zilberman M, Zaks TZ and Vogel SN:
Induction of proinflammatory and chemokine genes by
lipopolysaccharide and paclitaxel (Taxol) in murine and human
breast cancer cell lines. Cytokine. 15:156–165. 2001.
|
|
14
|
Ilvesaro JM, Merrell MA, Li L, et al:
Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular
invasion. Mol Cancer Res. 6:1534–1543. 2008.
|
|
15
|
Ilvesaro JM, Merrell MA, Swain TM, et al:
Toll like receptor-9 agonists stimulate prostate cancer invasion in
vitro. Prostate. 67:774–781. 2007.
|
|
16
|
Merrell MA, Ilvesaro JM, Lehtonen N, et
al: Toll-like receptor 9 agonists promote cellular invasion by
increasing matrix metalloproteinase activity. Mol Cancer Res.
4:437–447. 2006.
|
|
17
|
Wang C, Cao S, Yan Y, et al: TLR9
expression in glioma tissues correlated to glioma progression and
the prognosis of GBM patients. BMC Cancer. 10:4152010.
|
|
18
|
Jukkola-Vuorinen A, Rahko E, Vuopala KS,
et al: Toll-like receptor-9 expression is inversely correlated with
estrogen receptor status in breast cancer. J Innate Immun. 1:59–68.
2009.
|
|
19
|
Väisänen MR, Jukkola-Vuorinen A, Vuopala
KS, Selander KS and Vaarala MH: Expression of Toll-like receptor-9
is associated with poor progression-free survival in prostate
cancer. Oncol Lett. 5:1659–1663. 2013.
|
|
20
|
Väisänen MR, Väisänen T, Jukkola-Vuorinen
A, et al: Expression of toll-like receptor-9 is increased in poorly
differentiated prostate tumors. Prostate. 70:817–824. 2010.
|
|
21
|
Berger R, Fiegl H, Goebel G, et al:
Toll-like receptor 9 expression in breast and ovarian cancer is
associated with poorly differentiated tumors. Cancer Sci.
101:1059–1066. 2010.
|
|
22
|
Grauer OM, Molling JW, Bennink E, et al:
TLR ligands in the local treatment of established intracerebral
murine gliomas. J Immunol. 181:6720–6729. 2008.
|
|
23
|
Zhao D, Alizadeh D, Zhang L, et al: Carbon
nanotubes enhance CpG uptake and potentiate antiglioma immunity.
Clin Cancer Res. 17:771–782. 2011.
|
|
24
|
Ruan K, Song G and Ouyang G: Role of
hypoxia in the hallmarks of human cancer. J Cell Biochem.
107:1053–1062. 2009.
|
|
25
|
Bar EE: Glioblastoma, cancer stem cells
and hypoxia. Brain Pathol. 21:119–129. 2011.
|
|
26
|
Kuhlicke J, Frick JS, Morote-Garcia JC,
Rosenberger P and Eltzschig HK: Hypoxia inducible factor (HIF)-1
coordinates induction of Toll-like receptors TLR2 and TLR6 during
hypoxia. PLoS One. 2:e13642007.
|
|
27
|
Filippova N, Yang X, King P and Nabors LB:
Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by
Cdk5 affects centrosome function. J Biol Chem. 287:32277–32287.
2012.
|
|
28
|
Filippova N, Yang X, Wang Y, et al: The
RNA-binding protein HuR promotes glioma growth and treatment
resistance. Mol Cancer Res. 9:648–659. 2011.
|
|
29
|
Sandholm J, Kauppila JH, Pressey C, et al:
Estrogen receptor-α and sex steroid hormones regulate Toll-like
receptor-9 expression and invasive function in human breast cancer
cells. Breast Cancer Res Treat. 132:411–419. 2012.
|
|
30
|
Merrell M, Suarez-Cuervo C, Harris KW,
Väänänen HK and Selander KS: Bisphosphonate induced growth
inhibition of breast cancer cells is augmented by p38 inhibition.
Breast Cancer Res Treat. 81:231–241. 2003.
|
|
31
|
Tuomela J, Sandholm J, Karihtala P, et al:
Low TLR9 expression defines an aggressive subtype of
triple-negative breast cancer. Breast Cancer Res Treat.
135:481–493. 2012.
|
|
32
|
Kauppila JH, Karttunen TJ, Saarnio J, et
al: Short DNA sequences and bacterial DNA induce esophageal,
gastric, and colorectal cancer cell invasion. APMIS. 121:511–522.
2013.
|
|
33
|
Muñoz-Nájar UM, Neurath KM, Vumbaca F and
Claffey KP: Hypoxia stimulates breast carcinoma cell invasion
through MT1-MMP and MMP-2 activation. Oncogene. 25:2379–2392.
2006.
|
|
34
|
Arvelo F and Cotte C: Hypoxia in cancer
malignity. Review Invest Clin. 50:529–546. 2009.(In Spanish).
|
|
35
|
Langton KP, Barker MD and McKie N:
Localization of the functional domains of human tissue inhibitor of
metalloproteinases-3 and the effects of a Sorsby’s fundus dystrophy
mutation. J Biol Chem. 273:16778–16781. 1998.
|
|
36
|
Stricklin GP: Human fibroblast tissue
inhibitor of metalloproteinases: glycosylation and function. Coll
Relat Res. 6:219–228. 1986.
|
|
37
|
Hemmi H, Takeuchi O, Kawai T, et al: A
Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745.
2000.
|
|
38
|
Lande R, Gregorio J, Facchinetti V, et al:
Plasmacytoid dendritic cells sense self-DNA coupled with
antimicrobial peptide. Nature. 449:564–569. 2007.
|
|
39
|
Meng Y, Kujas M, Marie Y, et al:
Expression of TLR9 within human glioblastoma. J Neurooncol.
88:19–25. 2008.
|
|
40
|
Chiang CY, Engel A, Opaluch AM, et al:
Cofactors required for TLR7- and TLR9-dependent innate immune
responses. Cell Host Microbe. 11:306–318. 2012.
|
|
41
|
Yang L, Lin C, Wang L, Guo H and Wang X:
Hypoxia and hypoxia-inducible factors in glioblastoma multiforme
progression and therapeutic implications. Exp Cell Res.
318:2417–2426. 2012.
|
|
42
|
Chen W, Hartman R, Ayer R, et al: Matrix
metalloproteinases inhibition provides neuroprotection against
hypoxia-ischemia in the developing brain. J Neurochem. 111:726–736.
2009.
|
|
43
|
Méndez O, Zavadil J, Esencay M, et al:
Knock down of HIF-1alpha in glioma cells reduces migration in vitro
and invasion in vivo and impairs their ability to form tumor
spheres. Mol Cancer. 9:1332010.
|
|
44
|
Lu DY, Yu WH, Yeh WL, et al:
Hypoxia-induced matrix metalloproteinase-13 expression in
astrocytes enhances permeability of brain endothelial cells. J Cell
Physiol. 220:163–173. 2009.
|
|
45
|
Bamboat ZM, Balachandran VP, Ocuin LM,
Obaid H, Plitas G and DeMatteo RP: Toll-like receptor 9 inhibition
confers protection from liver ischemia-reperfusion injury.
Hepatology. 51:621–632. 2010.
|
|
46
|
Rifkin IR, Leadbetter EA, Busconi L,
Viglianti G and Marshak-Rothstein A: Toll-like receptors,
endogenous ligands, and systemic autoimmune disease. Immunol Rev.
204:27–42. 2005.
|
|
47
|
Tuomela J, Grönroos TJ, Valta MP, et al:
Fast growth associated with aberrant vasculature and hypoxia in
fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate
tumour xenografts. BMC Cancer. 10:5962010.
|
|
48
|
Barcellos-Hoff MH, Newcomb EW, Zagzag D
and Narayana A: Therapeutic targets in malignant glioblastoma
microenvironment. Semin Radiat Oncol. 19:163–170. 2009.
|
|
49
|
Kimbro KS and Simons JW: Hypoxia-inducible
factor-1 in human breast and prostate cancer. Endocr Relat Cancer.
13:739–749. 2006.
|
|
50
|
Nicholas SA, Oniku AE and Sumbayev VV:
Myeloid cell death associated with Toll-like receptor 7/8-mediated
inflammatory response. Implication of ASK1, HIF-1 alpha, IL-1 beta
and TNF-alpha. Mol Immunol. 48:240–247. 2010.
|
|
51
|
Paone A, Galli R, Gabellini C, et al:
Toll-like receptor 3 regulates angiogenesis and apoptosis in
prostate cancer cell lines through hypoxia-inducible factor 1
alpha. Neoplasia. 12:539–549. 2010.
|
|
52
|
Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS
and Lee JY: Hypoxic stress up-regulates the expression of Toll-like
receptor 4 in macrophages via hypoxia-inducible factor. Immunology.
129:516–524
|
|
53
|
Sinha S, Koul N, Dixit D, Sharma V and Sen
E: IGF-1 induced HIF-1α-TLR9 cross talk regulates inflammatory
responses in glioma. Cell Signal. 23:1869–1875. 2011.
|
